Axel Hoos
Biotechnology
Imugene
Australia
Biography
Dr. Axel Hoos is vice president, Oncology R&D at Glaxo Smith Kline Pharmaceuticals (GSK), where he directs clinical and translational research on molecular mechanisms of cancer and tumor-host interactions for rational combination of therapies to optimize patient outcomes. Prior to his current role, Dr. Hoos was the medical lead in immunology/oncology at Bristol-Myers Squibb (BMS) where he developed the Yervoy (Ipilimumab; anti CTLA-4) monoclonal antibody in melanoma and other indications. Yervoy is the first therapy to extend survival in metastatic melanoma.
Research Interest
Genome
